These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 23950643)

  • 1. How nanotechnology can enhance docetaxel therapy.
    Zhang L; Zhang N
    Int J Nanomedicine; 2013; 8():2927-41. PubMed ID: 23950643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel nanotechnology in anticancer therapy.
    Zhao P; Astruc D
    ChemMedChem; 2012 Jun; 7(6):952-72. PubMed ID: 22517723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocarriers for anticancer drugs--new trends in nanomedicine.
    Drbohlavova J; Chomoucka J; Adam V; Ryvolova M; Eckschlager T; Hubalek J; Kizek R
    Curr Drug Metab; 2013 Jun; 14(5):547-64. PubMed ID: 23687925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current development in nanoformulations of docetaxel.
    Tan Q; Liu X; Fu X; Li Q; Dou J; Zhai G
    Expert Opin Drug Deliv; 2012 Aug; 9(8):975-90. PubMed ID: 22703284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.
    Sohail MF; Rehman M; Sarwar HS; Naveed S; Salman O; Bukhari NI; Hussain I; Webster TJ; Shahnaz G
    Int J Nanomedicine; 2018; 13():3145-3161. PubMed ID: 29922053
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kazemi M; Emami J; Hasanzadeh F; Minaiyan M; Mirian M; Lavasanifar A; Mokhtari M
    Recent Pat Anticancer Drug Discov; 2020; 15(4):341-359. PubMed ID: 33023456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.
    Gao W; Xiang B; Meng TT; Liu F; Qi XR
    Biomaterials; 2013 May; 34(16):4137-4149. PubMed ID: 23453200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
    Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
    Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy using nanotechnology: focus on cancer.
    Sanna V; Pala N; Sechi M
    Int J Nanomedicine; 2014; 9():467-83. PubMed ID: 24531078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the Anti-Ovarian Cancer Activity of Docetaxel by Self-Assemble Micelles and Thermosensitive Hydrogel Drug Delivery System.
    Xu G; Zhu C; Li B; Wang T; Wan J; Zhang Y; Huang J; Yang D; Shen Y
    J Biomed Nanotechnol; 2020 Jan; 16(1):40-53. PubMed ID: 31996284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy.
    Zhi D; Yang T; Yang J; Fu S; Zhang S
    Acta Biomater; 2020 Jan; 102():13-34. PubMed ID: 31759124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoways to overcome docetaxel resistance in prostate cancer.
    Ganju A; Yallapu MM; Khan S; Behrman SW; Chauhan SC; Jaggi M
    Drug Resist Updat; 2014 Apr; 17(1-2):13-23. PubMed ID: 24853766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
    Rafiei P; Haddadi A
    Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles.
    Jiang S; Gong X; Zhao X; Zu Y
    Drug Deliv; 2015 Feb; 22(2):206-13. PubMed ID: 24471890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity.
    Yuan Q; Han J; Cong W; Ge Y; Ma D; Dai Z; Li Y; Bi X
    Int J Nanomedicine; 2014; 9():4829-46. PubMed ID: 25378924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
    Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
    J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
    Koopaei MN; Dinarvand R; Amini M; Rabbani H; Emami S; Ostad SN; Atyabi F
    Int J Nanomedicine; 2011; 6():1903-12. PubMed ID: 21931485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted poly (L-γ-glutamyl glutamine) nanoparticles of docetaxel against folate over-expressed breast cancer cells.
    Tavassolian F; Kamalinia G; Rouhani H; Amini M; Ostad SN; Khoshayand MR; Atyabi F; Tehrani MR; Dinarvand R
    Int J Pharm; 2014 Jun; 467(1-2):123-38. PubMed ID: 24680951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
    Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
    J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.